Endocrinological profiles in patients with prostate cancer treated with LHRH antagonist

Endocrinological profiles in patients with prostate cancer treated with LHRH antagonist - Endocrinological profiles of LHRH antagonist

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011990

Enrollment

Registered

2013-10-08

Start date

2013-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

LHRH antagonist, degarelix

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with prostate cancer treated with LHRH antagonist, Degarelix

Exclusion criteria

Exclusion criteria: 1. Patients treated with concomitant anti-androgens. 2. Patients treated with concomitant medicines that affect serum sex hormone levels.

Design outcomes

Primary

Measure	Time frame
Changes of serum sex and peptide hormones.	—

Countries

Japan

Contacts

Public ContactKazuhiro Suzuki

Gunma University Graduate School of Medicine Department of Urology

kazu@gunma-u.ac.jp027-220-8300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026